Literature DB >> 25972321

Lymphoplasmacytic lymphoma and marginal zone lymphoma in the bone marrow: paratrabecular involvement as an important distinguishing feature.

Assia Bassarova1, Gunhild Trøen2, Signe Spetalen3, Francesca Micci4, Anne Tierens5, Jan Delabie6.   

Abstract

OBJECTIVES: The differential diagnosis between bone marrow involvement by lymphoplasmacytic lymphoma (LPL) and marginal zone lymphoma (MZL) is challenging because histology and immunophenotype of both diseases overlap. We revisited the diagnostic pathology features of both diseases in the bone marrow.
METHODS: We studied a series of bone marrow trephine biopsy specimens from 59 patients with Waldenström macroglobulinemia without extramedullary involvement and bone marrow biopsy specimens from 23 patients with well-characterized MZL who also had bone marrow involvement. H&E- and immunoperoxidase-stained sections of bone marrow trephine biopsy specimens as well as flow cytometry and classic cytogenetics performed on aspirations were reviewed. The study was complemented with MYD88 L265P mutation analysis of all samples.
RESULTS: The most distinguishing features of LPL with respect to MZL were focal paratrabecular involvement (P < .001), the presence of lymphoplasmacytoid cells (P < .001) and Dutcher bodies (P < .001), increased numbers of mast cells (P < .001), and the MYD88 L265P mutation (P < .001).
CONCLUSIONS: LPL can be reliably distinguished from MZL in the bone marrow by using a combination of pathology characteristics. Our findings stress the diagnostic importance of using the combination of the following parameters for a correct LPL diagnosis: paratrabecular infiltration, the presence of lymphoplasmacytoid cells and cells with Dutcher bodies, and an increased number of mast cells in addition to the presence of MYD88 mutation. Copyright© by the American Society for Clinical Pathology.

Entities:  

Keywords:  Bone marrow; Hematopathology; Lymphoplasmacytic lymphoma; Marginal zone lymphoma; Paratrabecular

Mesh:

Substances:

Year:  2015        PMID: 25972321     DOI: 10.1309/AJCP6ZODWV1CIDME

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  4 in total

1.  B-Cell Lymphoma Patient-Derived Xenograft Models Enable Drug Discovery and Are a Platform for Personalized Therapy.

Authors:  Leo Zhang; Krystle Nomie; Hui Zhang; Taylor Bell; Lan Pham; Sabah Kadri; Jeremy Segal; Shaoying Li; Shouhao Zhou; David Santos; Shawana Richard; Shruti Sharma; Wendy Chen; Onyekachukwu Oriabure; Yang Liu; Shengjian Huang; Hui Guo; Zhihong Chen; Wenjing Tao; Carrie Li; Jack Wang; Bingliang Fang; Jacqueline Wang; Lei Li; Maria Badillo; Makhdum Ahmed; Selvi Thirumurthi; Steven Y Huang; Yiping Shao; Laura Lam; Qing Yi; Y Lynn Wang; Michael Wang
Journal:  Clin Cancer Res       Date:  2017-03-27       Impact factor: 12.531

Review 2.  Waldenstrom's Macroglobulinemia: An Update.

Authors:  Maddalena Mazzucchelli; Anna Maria Frustaci; Marina Deodato; Roberto Cairoli; Alessandra Tedeschi
Journal:  Mediterr J Hematol Infect Dis       Date:  2018-01-01       Impact factor: 2.576

3.  Bone Marrow Involvement by Aggressive B Cell Lymphoma Undetected by Aspirate Immunophenotyping.

Authors:  Habib Moshref Razavi
Journal:  J Hematol       Date:  2021-02-06

4.  Blurry Vision as a Presentation of Waldenström's Macroglobulinemia: A Case Report With Review of Current Management.

Authors:  Tyler Nicholas Adams; Rachna Jetly-Shridhar; Dat Tran; Brian C Boulmay
Journal:  J Investig Med High Impact Case Rep       Date:  2022 Jan-Dec
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.